Diagnostic Accuracy of FibroScan and Factors Affecting Measurements

Satoshi Oeda, Kenichi Tanaka, Ayaka Oshima, Yasue Matsumoto, Eisaburo Sueoka, Hirokazu Takahashi, Satoshi Oeda, Kenichi Tanaka, Ayaka Oshima, Yasue Matsumoto, Eisaburo Sueoka, Hirokazu Takahashi

Abstract

Evaluating liver steatosis and fibrosis is important for patients with non-alcoholic fatty liver disease. Although liver biopsy and pathological assessment is the gold standard for these conditions, this technique has several disadvantages. The evaluation of steatosis and fibrosis using ultrasound B-mode imaging is qualitative and subjective. The liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) determined using FibroScan are the evidence-based non-invasive measures of liver fibrosis and steatosis, respectively. The LSM and CAP measurements are carried out simultaneously, and the median values of more than ten valid measurements are used to quantify liver fibrosis and steatosis. Here, we demonstrate that the reliability of the LSM depends on the interquartile range to median ratio (IQR/Med), but CAP values do not depend on IQR/Med. In addition, the LSM is affected by inflammation, congestion, and cholestasis in addition to fibrosis, while CAP values are affected by the body mass index in addition to steatosis. We also show that the M probe provides higher LSM values but lower CAP values than the XL probe in the same population. However, there was no statistically significant difference between the diagnostic accuracies of the two probes. These findings are important to understand the reliability of FibroScan measurements and the factors influencing measurement values for all patients.

Keywords: controlled attenuation parameter; hepatic inflammation; hepatic steatosis; liver stiffness measurement; non-alcoholic fatty liver disease; transient elastography.

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Bedossa P., Poitou C., Veyrie N., Bouillot J.-L., Basdevant A., Paradis V., Tordjman J., Clement K. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56:1751–1759. doi: 10.1002/hep.25889.
    1. Angulo P., Kleiner D.E., Dam-Larsen S., Adams L.A., Björnsson E.S., Charatcharoenwitthaya P., Mills P.R., Keach J.C., Lafferty H.D., Stahler A., et al. Liver Fibrosis, but No Other Histologic Features, Is Associated with Long-term Outcomes of Patients with Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149:389–397.e10. doi: 10.1053/j.gastro.2015.04.043.
    1. Dulai P.S., Singh S., Patel J., Soni M., Prokop L.J., Younossi Z., Sebastiani G., Ekstedt M., Hagstrom H., Nasr P., et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017;65:1557–1565. doi: 10.1002/hep.29085.
    1. Piccinino F., Sagnelli E., Pasquale G., Giusti G., Battocchia A., Bernardi M., Bertolazzi R., Bianchi F., Brunelli E., Budillon G., et al. Complications following percutaneous liver biopsy. J. Hepatol. 1986;2:165–173. doi: 10.1016/S0168-8278(86)80075-7.
    1. Ratziu V., Charlotte F., Heurtier A., Gombert S., Giral P., Bruckert E., Grimaldi A., Capron F., Poynard T. Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease. Gastroenterology. 2005;128:1898–1906. doi: 10.1053/j.gastro.2005.03.084.
    1. Kuwashiro T., Takahashi H., Hyogo H., Ogawa Y., Imajo K., Yoneda M., Nakahara T., Oeda S., Tanaka K., Amano Y., et al. Discordant pathological diagnosis of non-alcoholic fatty liver disease: A prospective multicenter study. JGH Open. 2019;4:497–502. doi: 10.1002/jgh3.12289.
    1. Tincopa M.A. Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis. Endocrinol. Diabetes Metab. 2020;3:00177. doi: 10.1002/edm2.177.
    1. Yajima Y., Ohta K., Narui T., Abe R., Suzuki H., Ohtsuki M. Ultrasonographical Diagnosis of Fatty Liver: Significance of the Liver-Kidney Contrast. Tohoku J. Exp. Med. 1983;139:43–50. doi: 10.1620/tjem.139.43.
    1. Marshall R.H., Eissa M., Bluth E., Gulotta P.M., Davis N.K. Hepatorenal Index as an Accurate, Simple, and Effective Tool in Screening for Steatosis. Am. J. Roentgenol. 2012;199:997–1002. doi: 10.2214/AJR.11.6677.
    1. Shen L. Correlation between ultrasonographic and pathologic diagnosis of liver fibrosis due to chronic virus hepatitis. World J. Gastroenterol. 2006;12:1292–1295. doi: 10.3748/wjg.v12.i8.1292.
    1. Yoneda M., Honda Y., Nogami A., Imajo K., Nakajima A. Advances in ultrasound elastography for nonalcoholic fatty liver disease. J. Med Ultrason. 2020:1–13. doi: 10.1007/s10396-020-01040-8.
    1. Honda Y., Yoneda M., Imajo K., Nakajima A. Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. Int. J. Mol. Sci. 2020;21:4039. doi: 10.3390/ijms21114039.
    1. Hsu C., Caussy C., Imajo K., Chen J., Singh S., Kaulback K., Le M.-D., Hooker J., Tu X., Bettencourt R., et al. Magnetic Resonance vs Transient Elastography Analysis of Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants. Clin. Gastroenterol. Hepatol. 2019;17:630–637.e8. doi: 10.1016/j.cgh.2018.05.059.
    1. Zhang X., Wong G.L.-H., Wong V.W.-S. Application of transient elastography in nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 2019;26:128–141. doi: 10.3350/cmh.2019.0001n.
    1. Newsome P.N., Sasso M., Deeks J.J., Paredes A., Boursier J., Chan W.-K., Yilmaz Y., Czernichow S., Zheng M.-H., Wong V.W.-S., et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: A prospective derivation and global validation study. Lancet Gastroenterol. Hepatol. 2020;5:362–373. doi: 10.1016/S2468-1253(19)30383-8.
    1. Oeda S., Takahashi H., Imajo K., Seko Y., Kobayashi T., Ogawa Y., Moriguchi M., Yoneda M., Anzai K., Irie H., et al. Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: Comparison between M and XL probes. Hepatol. Res. 2020;50:831–839. doi: 10.1111/hepr.13508.
    1. Eslam M., Sanyal A.J., George J., Neuschwander-Tetri B., Tiribelli C., Kleiner D.E., Brunt E., Bugianesi E., Yki-Järvinen H., Grønbæk H., et al. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158:1999–2014.e1. doi: 10.1053/j.gastro.2019.11.312.
    1. Eslam M., Sarin S.K., Wong V.W.-S., Fan J.-G., Kawaguchi T., Ahn S.H., Zheng M.-H., Shiha G., Yilmaz Y., Gani R., et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol. Int. 2020 doi: 10.1007/s12072-020-10094-2.
    1. Chan W.-K., Mustapha N.R.N., Wong G.L.-H., Wong V.W.-S., Mahadeva S. Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population. United Eur. Gastroenterol. J. 2016;5:76–85. doi: 10.1177/2050640616646528.
    1. Yoneda M., Fujita K., Inamori M., Nakajima A., Tamano M., Hiraishi H. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD) Gut. 2007;56:1330–1331. doi: 10.1136/gut.2007.126417.
    1. Yoneda M., Mawatari H., Fujita K., Endo H., Iida H., Nozaki Y., Yonemitsu K., Higurashi T., Takahashi H., Kobayashi N., et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD) Dig. Liver Dis. 2008;40:371–378. doi: 10.1016/j.dld.2007.10.019.
    1. Nobili V., Vizzutti F., Arena U., Abraldes J.G., Marra F., Pietrobattista A., Fruhwirth R., Marcellini M., Pinzani M. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology. 2008;48:442–448. doi: 10.1002/hep.22376.
    1. Wong V.W.-S., Vergniol J., Wong G.L.-H., Foucher J., Chan H.L.-Y., Le Bail B., Choi P.C.-L., Kowo M., Chan A.W.-H., Merrouche W., et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51:454–462. doi: 10.1002/hep.23312.
    1. Lupsor-Platon M., Badea R., Stefănescu H., Grigorescu M., Serban A., Radu C., Crişan D., Sparchez Z., Iancu S., Maniu A. Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. J. Gastrointest. Liver Dis. 2010;19:53–60.
    1. Friedrich-Rust M., Hadji-Hosseini H., Kriener S., Herrmann E., Sircar I., Kau A., Zeuzem S., Bojunga J. Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis. Eur. Radiol. 2010;20:2390–2396. doi: 10.1007/s00330-010-1820-9.
    1. Petta S., Di Marco V., Cammà C., Butera G., Cabibi D., Craxi A. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: The effects of body mass index. Aliment. Pharmacol. Ther. 2011;33:1350–1360. doi: 10.1111/j.1365-2036.2011.04668.x.
    1. Friedrich-Rust M., Romen D., Vermehren J., Kriener S., Sadet D., Herrmann E., Zeuzem S., Bojunga J. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur. J. Radiol. 2012;81:e325–e331. doi: 10.1016/j.ejrad.2011.10.029.
    1. Wong V.W.-S., Vergniol J., Wong G.L.-H., Foucher J., Chan A.W.-H., Chermak F., Choi P.C.-L., Merrouche W., Chu S.H.-T., Pesque S., et al. Liver Stiffness Measurement Using XL Probe in Patients with Nonalcoholic Fatty Liver Disease. Am. J. Gastroenterol. 2012;107:1862–1871. doi: 10.1038/ajg.2012.331.
    1. Kumar R., Rastogi A., Sharma M.K., Bhatia V., Tyagi P., Sharma P., Garg H., Kumar K.N.C., Bihari C., Sarin S.K. Liver Stiffness Measurements in Patients with Different Stages of Nonalcoholic Fatty Liver Disease: Diagnostic Performance and Clinicopathological Correlation. Dig. Dis. Sci. 2013;58:265–274. doi: 10.1007/s10620-012-2306-1.
    1. Pathik P., Ravindra S., Ajay C., Prasad B., Jatin P., Prabha S. Fibroscan versus simple noninvasive screening tools in predicting fibrosis in high-risk nonalcoholic fatty liver disease patients from Western India. Ann. Gastroenterol. 2015;28:281–286.
    1. Imajo K., Kessoku T., Honda Y., Tomeno W., Ogawa Y., Mawatari H., Fujita K., Yoneda M., Taguri M., Hyogo H., et al. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease Than Transient Elastography. Gastroenterology. 2016;150:626–637.e7. doi: 10.1053/j.gastro.2015.11.048.
    1. Eddowes P.J., Sasso M., Allison M., Tsochatzis E., Anstee Q.M., Sheridan D., Guha I.N., Cobbold J.F., Deeks J.J., Paradis V., et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156:1717–3170. doi: 10.1053/j.gastro.2019.01.042.
    1. Oeda S., Takahashi H., Imajo K., Seko Y., Ogawa Y., Moriguchi M., Yoneda M., Anzai K., Aishima S., Kage M., et al. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: A multicenter prospective study. J. Gastroenterol. 2019;55:428–440. doi: 10.1007/s00535-019-01635-0.
    1. Cardoso A.C., Cravo C., Calçado F.L., Rezende G., Campos C.F.F., Neto J.M.A., Luz R.P., Soares J.A.S., Moraes-Coelho H.S., Leite N.C., et al. The performance of M and XL probes of FibroScan for the diagnosis of steatosis and fibrosis on a Brazilian nonalcoholic fatty liver disease cohort. Eur. J. Gastroenterol. Hepatol. 2020;32:231–238. doi: 10.1097/MEG.0000000000001496.
    1. Lucidarme D., Foucher J., Le Bail B., Vergniol J., Castera L., Duburque C., Forzy G., Filoche B., Couzigou P., De Lédinghen V. Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology. 2008;49:1083–1089. doi: 10.1002/hep.22748.
    1. Boursier J., Zarski J.-P., De Ledinghen V., Rousselet M.-C., Sturm N., LeBail B., Fouchard-Hubert I., Gallois Y., Oberti F., Bertrais S., et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology. 2013;57:1182–1191. doi: 10.1002/hep.25993.
    1. Kettaneh A., Marcellin P., Douvin C., Poupon R., Ziol M., Beaugrand M., De Lédinghen V. Features associated with success rate and performance of fibroscan measurements for the diagnosis of cirrhosis in HCV patients: A prospective study of 935 patients. J. Hepatol. 2007;46:628–634. doi: 10.1016/j.jhep.2006.11.010.
    1. Coco B., Oliveri F., Maina A.M., Ciccorossi P., Sacco R., Colombatto P., Bonino F., Brunetto M.R. Transient elastography: A new surrogate marker of liver fibrosis influenced by major changes of transaminases. J. Viral Hepat. 2007;14:360–369. doi: 10.1111/j.1365-2893.2006.00811.x.
    1. Arena U., Vizzutti F., Corti G., Ambu S., Stasi C., Bresci S., Moscarella S., Boddi V., Petrarca A., Laffi G., et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology. 2007;47:380–384. doi: 10.1002/hep.22007.
    1. Sagir A., Erhardt A., Schmitt M., Häussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology. 2007;47:592–595. doi: 10.1002/hep.22056.
    1. Millonig G., Friedrich S., Adolf S., Fonouni H., Golriz M., Mehrabi A., Stiefel P., Pöschl G., Büchler M.W., Seitz H.K., et al. Liver stiffness is directly influenced by central venous pressure. J. Hepatol. 2010;52:206–210. doi: 10.1016/j.jhep.2009.11.018.
    1. Mueller S., Millonig G., Friedrich S., Welker A., Becker P., Reimann F., Seitz H.K. 17 Extrahepatic Cholestasis Increases Liver Stiffness (Fibroscan ®) Irrespective of Fibrosis. Gastroenterology. 2008;134:1718–1723. doi: 10.1016/S0016-5085(08)60013-X.
    1. Loustaud-Ratti V., Cypierre A., Rousseau A., Yagoubi F., Abraham J., Fauchais A.-L., Carrier P., Lefebvre A., Bordessoule D., Vidal E., et al. Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool. Amyloid. 2011;18:19–24. doi: 10.3109/13506129.2010.543443.
    1. Lanzi A., Gianstefani A., Mirarchi M.G., Pini P., Conti F., Bolondi L. Liver AL amyloidosis as a possible cause of high liver stiffness values. Eur. J. Gastroenterol. Hepatol. 2010;22:895–897. doi: 10.1097/MEG.0b013e3283309d5b.
    1. Mueller S. Liver stiffness: A novel parameter for the diagnosis of liver disease. Hepatic Med. Evid. Res. 2010;2:49–67. doi: 10.2147/HMER.S7394.
    1. Mueller S., Englert S., Seitz H.K., Badea R., Erhardt A., Bozaari B., Beaugrand M., Lupsor-Platon M. Inflammation-adapted liver stiffness values for improved fibrosis staging in patients with hepatitis C virus and alcoholic liver disease. Liver Int. 2015;35:2514–2521. doi: 10.1111/liv.12904.
    1. Mueller S., Millonig G., Sarovska L., Friedrich S., Reimann F.M., Pritsch M., Eisele S., Stickel F., Longerich T., Schirmacher P., et al. Increased liver stiffness in alcoholic liver disease: Differentiating fibrosis from steatohepatitis. World J. Gastroenterol. 2010;16:966–972. doi: 10.3748/wjg.v16.i8.966.
    1. Mederacke I., Wursthorn K., Kirschner J., Rifai K., Manns M.P., Wedemeyer H., Bahr M.J. Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver Int. 2009;29:1500–1506. doi: 10.1111/j.1478-3231.2009.02100.x.
    1. Berzigotti A., De Gottardi A., Vukotic R., Siramolpiwat S., Abraldes J.G., García-Pagan J.C., Bosch J. Effect of Meal Ingestion on Liver Stiffness in Patients with Cirrhosis and Portal Hypertension. PLoS ONE. 2013;8:e58742. doi: 10.1371/journal.pone.0058742.
    1. Arena U., Platon M.L., Stasi C., Moscarella S., Assarat A., Bedogni G., Piazzolla V., Badea R., Laffi G., Marra F., et al. Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology. 2013;58:65–72. doi: 10.1002/hep.26343.
    1. Sasso M., Beaugrand M., De Ledinghen V., Douvin C., Marcellin P., Poupon R., Sandrin L., Miette V. Controlled Attenuation Parameter (CAP): A Novel VCTE™ Guided Ultrasonic Attenuation Measurement for the Evaluation of Hepatic Steatosis: Preliminary Study and Validation in a Cohort of Patients with Chronic Liver Disease from Various Causes. Ultrasound Med. Biol. 2010;36:1825–1835. doi: 10.1016/j.ultrasmedbio.2010.07.005.
    1. Shi K.-Q., Tang J.-Z., Zhu X.-L., Ying L., Li D.-W., Gao J., Fang Y.-X., Li G.-L., Song Y.-J., Deng Z.-J., et al. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: A meta-analysis of diagnostic accuracy. J. Gastroenterol. Hepatol. 2014;29:1149–1158. doi: 10.1111/jgh.12519.
    1. Chan W.-K., Mustapha N.R.N., Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2014;29:1470–1476. doi: 10.1111/jgh.12557.
    1. Darweesh S.K., Omar H., Medhat E., Aziz R.A.A.-A., Ayman H., Saad Y., Yosry A. The clinical usefulness of elastography in the evaluation of nonalcoholic fatty liver disease patients. Eur. J. Gastroenterol. Hepatol. 2019;31:1010–1016. doi: 10.1097/meg.0000000000001365.
    1. Caussy C., Alquiraish M.H., Nguyen P., Hernandez C., Cepin S., Fortney L.E., Ajmera V., Bettencourt R., Collier S., Hooker J., et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. Hepatology. 2018;67:1348–1359. doi: 10.1002/hep.29639.
    1. Myers R.P., Pollett A., Kirsch R., Pomier-Layrargues G., Beaton M., Levstik M., Duarte-Rojo A., Wong D., Crotty P., Elkashab M. Controlled Attenuation Parameter (CAP): A noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012;32:902–910. doi: 10.1111/j.1478-3231.2012.02781.x.
    1. Jung K.S., Kim B.K., Kim S.U., Chon Y.E., Cheon K.H., Kim S.B., Lee S.H., Ahn S.S., Park J.Y., Kim D.Y., et al. Factors Affecting the Accuracy of Controlled Attenuation Parameter (CAP) in Assessing Hepatic Steatosis in Patients with Chronic Liver Disease. PLoS ONE. 2014;9:e98689. doi: 10.1371/journal.pone.0098689.
    1. Wong V.W.-S., Petta S., Hiriart J.-B., Cammà C., Wong G.L.H., Marra F., Vergniol J., Chan A.W.H., Tuttolomondo A., Merrouche W., et al. Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. J. Hepatol. 2017;67:577–584. doi: 10.1016/j.jhep.2017.05.005.
    1. Sasso M., Tengher-Barna I., Ziol M., Miette V., Fournier C., Sandrin L., Poupon R., Cardoso A.-C., Marcellin P., Douvin C., et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan (®): Validation in chronic hepatitis C. J Viral Hepat. 2012;19:244–253.
    1. Kumar M., Rastogi A., Singh T., Behari C., Gupta E., Garg H., Kumar M., Bhatia V., Sarin S.K. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: Does etiology affect performance? J. Gastroenterol. Hepatol. 2013;28:1194–1201. doi: 10.1111/jgh.12134.
    1. Chon Y.E., Jung K.S., Kim S.U., Park J.Y., Park Y.N., Kim D.Y., Ahn S.H., Chon C.Y., Lee H.W., Park Y., et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: A prospective study of a native Korean population. Liver Int. 2013;34:102–109. doi: 10.1111/liv.12282.
    1. Shen F. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World J. Gastroenterol. 2014;20:4702–4711. doi: 10.3748/wjg.v20.i16.4702.
    1. Mi Y., Shi Q.-Y., Xu L., Shi R.-F., Liu Y.-G., Li P., Shen F., Lu W., Fan J.-G. Controlled Attenuation Parameter for Noninvasive Assessment of Hepatic Steatosis Using Fibroscan®: Validation in Chronic Hepatitis B. Dig. Dis. Sci. 2014;60:243–251. doi: 10.1007/s10620-014-3341-x.
    1. Ratchatasettakul K., Rattanasiri S., Promson K., Sringam P., Sobhonslidsuk A. The inverse effect of meal intake on controlled attenuation parameter and liver stiffness as assessed by transient elastography. BMC Gastroenterol. 2017;17:50. doi: 10.1186/s12876-017-0609-6.
    1. Silva M., Moreira P.C., Peixoto A., Santos A.L., Lopes S., Goncalves R., Pereira P., Cardoso H., Macedo G. Effect of Meal Ingestion on Liver Stiffness and Controlled Attenuation Parameter. GE Port. J. Gastroenterol. 2018;26:99–104. doi: 10.1159/000488505.
    1. Sasso M., Audière S., Kemgang A., Gaouar F., Corpechot C., Chazouillères O., Fournier C., Golsztejn O., Prince S., Menu Y., et al. Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy. Ultrasound Med. Biol. 2016;42:92–103. doi: 10.1016/j.ultrasmedbio.2015.08.008.
    1. Myers R.P., Pomier-Layrargues G., Kirsch R., Pollett A., Duarte-Rojo A., Wong D., Beaton M., Levstik M., Crotty P., Elkashab M. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology. 2011;55:199–208. doi: 10.1002/hep.24624.
    1. Wong G.L.-H., Vergniol J., Lo P., Wong V.W.-S., Foucher J., Le Bail B., Choi P.C.-L., Chermak F., Leung K.-S., Merrouche W., et al. Non-invasive assessment of liver fibrosis with transient elastography (FibroScan®): Applying the cut-offs of M probe to XL probe. Ann. Hepatol. 2013;12:402–412. doi: 10.1016/S1665-2681(19)31341-9.
    1. Şirli R., Sporea I., Deleanu A., Culcea L., Szilaski M., Popescu A., Dănilă M. Comparison between the M and XL probes for liver fibrosis assessment by Transient Elastography. Med Ultrason. 2014;16:119–122. doi: 10.11152/mu.201.3.2066.162.rs1is2.
    1. Caussy C., Brissot J., Singh S., Bassirian S., Hernandez C., Bettencourt R., Rizo E., Richards L., Sirlin C.B., Loomba R. Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter with the M vs. the XL Probe in Patients with Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging–Proton Density Fat Fraction as the Standard. Clin. Gastroenterol. Hepatol. 2020;18:1842–1850. doi: 10.1016/j.cgh.2019.11.060.
    1. Chan W.-K., Mustapha N.R.N., Mahadeva S., Wong V.W.-S., Cheng J.Y.-K., Wong G.L.H. Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis? J. Gastroenterol. Hepatol. 2018;33:1787–1794. doi: 10.1111/jgh.14150.
    1. Sumida Y., Yoneda M., Seko Y., Ishiba H., Hara T., Toyoda H., Yasuda S., Kumada T., Hayashi H., Kobayashi T., et al. Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Diagnostics. 2020;10:579. doi: 10.3390/diagnostics10080579.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever